4 Biotech Stocks That More Than Doubled In 2016

(Click on image to enlarge)

Achaogen, Inc. (AKAO - Free Report) : South San Francisco, CA-based Achaogen is another company that had a phenomenal run this year mainly due to positive data on its lead pipeline candidate. Shares are up 116.7% YTD with the stock receiving a major boost earlier this month when the company reported positive late-stage data on plazomicin. The candidate achieved the primary endpoint of non-inferiority (for the FDA) and superiority (for the European Medicines Agency - EMA) compared to meropenem in patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). Results from another phase III study showed a lower rate of mortality or serious disease-related complications for plazomicin compared with colistin therapy in patients with serious infections due to carbapenem-resistant Enterobacteriaceae (CRE). Achaogen intends to seek FDA approval for the treatment in the second half of 2017 and EMA approval in 2018. 

(Click on image to enlarge)

While Exelixis, TESARO and Achaogen are all Zacks Rank #3 (Hold) stocks, CoLucid is a Zacks Rank #2 (Buy) stock. 

1 2 3
View single page >> |

Disclosure: Zacks.com contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.